Acemetacin, a carboxymethyl ester of indomethacin, is a potent anti-inflammatory drug developed by Boltze et al.
(1). It has previously been reported through phar macological and pharmacokinetic studies that the anti-inflammatory activity of aceme tacin is considered to be derived from its active metabolite, indomethacin (2) (3) (4) . It has generally been recognized that indomethacin and several other non-steroidal anti inflammatory drugs inhibit cyclooxygenase which is responsible for prostaglandin (PG) synthesis, and these inhibitory activities result in the anti-inflammatory action of these drugs. Recently, Arai and Aizawa (5) and Takeuchi et al. (6) reported that PGE was released in a large amount from inflamed synovial tissue of rats and that non-steroidal anti -inflammatory agents suppressed the inflammation and PGE release from inflamed tissue.
In this study, we examined the inhibitory effect of acemetacin on the release of PG from the inflamed synovial tissue both in vivo and in vitro, in order to confirm the possibility that acemetacin is a prodrug of indomethacin.
The following chemicals were used in this study: acemetacin (Troponwerke, West Germany), indomethacin (Sumitomokagaku, Osaka, Japan) and carrageenan (Sigma Chemical, U.S.A.). Male Wistar strain rats bred in our research laboratories (6-8 weeks old) were used after fasting for 24 hr.
Experiments were carried out according to the report of Takeuchi et al. (6) . One tenth ml of 1 % carrageenan solution was injected into the knee joint of the rat under ether anesthesia.
The rat was sacrificed by decapitation 6 hr after injection of car rageenan, and the synovial membrane was removed from the articular capsule and weighed after the synovial fluid was elimi nated with the use of filter paper. Then, the synovial membrane was minced with scissors, incubated in 1 ml of Krebs Henseleite solution at 37°C for 15 min, and transferred into 1 ml of Krebs Henseleite solution and again incubated for another 15 min. The first and second incubation media were combined, followed by 10 times dilution with phosphate buffer (50 mM, pH 6.8) containing 10 iig/ml of indomethacin.
In the in vivo study, test compounds suspended in 0.5% CIVIC solution were administered orally 1 hr before the car rageenan injection. On the other hand, in the in vitro study, a solution of test compound was mixed in incubation medium and incu bated with the synovial tissue. After pre incubation (37°C, 5 min), this medium was decanted, and the incubation was carried out twice (15 min x 2) as in the case of the in vivo study. The second and third incu bation media were combined and diluted as described above. These samples were stored at -20°C until assay. PGE2 contents were determined by a radioimmunoassay (RIA) technique using a PGE2 [1251] RIA kit (New England Nuclear, U.S.A.).
The weight of the synovial membrane and the amount of PGE2 released from the tissue were measured following the injection of carrageenan or 0.9% saline solution (Non inflamed group) into the knee joints of rats. As shown in Table 1 , both parameters were significantly increased as high as 1.5-2.4 times in the carrageenan-treated rats as compared with the non-inflamed group. These results paralleled the observation by Arai and Aizawa (5). They showed that PG release was proportional to the increase in the weight of the synovial tissue which was considered to be an indicator for inflammatory response.
When acemetacin and indome thacin were administered orally at equimolar doses, both compounds showed the same dose-dependent inhibitory effect on the PGE2 release from inflamed tissue (Table I) . At the same time, both agents prevented the increase of the weight of synovial tissue. Table 2 . Inhibitory effect of acemetacin and indomethacin on PGE2 release from inflamed synovial membrane induced by carrageenan in rats (in vitro)
Therefore, it was confirmed that orally administered acemetacin exhibited the anti inflammatory effect through PG synthesis inhibition. In the in vitro study where the inflamed synovial tissue was incubated with the test compounds, acemetacin prevented the PGE2 release only at the high concen tration of 10-5 M, while indomethacin dose dependently inhibited this process at the lower concentration of 10-7 M or at a higher concentration (Table 2) . Since the sup pressive activity of acemetacin on cyclo oxygenase has been reported to be about 30 times less potent than that of indomethacin in an in vitro study where the rabbits' kidney homogenate was used (2), the fact that acemetacin exhibits less potent inhibitory effect on PGE2 release from the synovial membrane in the in vitro study may suggest that the effect of acemetacin itself on the PG system in the inflamed tissue is a bit weaker than that of indomethacin.
These results coincided with the previous report indicating that anti-inflammatory effects of orally administered acemetacin were almost equivalent to those of indomethacin, although the effect of locally administered acemetacin on carrageenan and kaolin paw edema were obviously less potent than that of indome thacin (2) . It has previously been reported that orally administered acemetacin is converted to indomethacin almost com pletely, and the liver is the organ responsible for indomethacin formation from acemetacin (7). Therefore, it is concluded that the active metabolite of orally administered acemetacin, indomethacin, exerts the anti-inflammatory effect through the suppressive effects on the PG system. These results that acemetacin exhibits only negligible effects on the PG system may be concerned with the fact that the irritative effects of acemetacin on the gastric mucosa is far weaker than that of indomethacin (8) . 
